What is claimed is:

1. A compound of Formula III:



(III)

or a pharmaceutically acceptable salt thereof; wherein

R^{801} is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, 4-7 membered heterocycloalkyl containing 1-3 heteroatoms, phenyl or 5- or 6-membered heteroaryl, each of which is substituted with O-C_{1-6} alkyl-R_x or NH-C_{1-6} alkyl-R_x, wherein R_x is hydroxyl, O-C_{1-3} alkyl or NH-C_{1-3} alkyl, and R_x is optionally further substituted with O-C_{1-3} alkyl or NH-C_{1-3} alkyl except when R_x is hydroxyl; and R^{801} is optionally further substituted;

each of R^{802} and R^{803}, *independently* is H, halo, C_{1-4} alkyl, C_{1-6} alkoxyl or C_6-C_{10} aryloxy, each optionally substituted with one or more halo;

each of R^{804} and R^{805}, independently is C_{1-4} alkyl; and

R^{806} is $-Q_x$-T_x, wherein Q_x is a bond or C_{1-4} alkyl linker, T_x is H, optionally substituted C_{1-4} alkyl, optionally substituted C_3-C_8 cycloalkyl or optionally substituted 4- to 14-membered heterocycloalkyl, *provided that the compound is not*  .

2. The compound of claim 1, wherein Q_x is a bond or methyl linker, and T_x is tetrahydropyranyl, piperidinyl substituted by 1, 2, or 3 C_{1-4} alkyl groups, or cyclohexyl substituted by $N(C_{1-4}$ alkyl$)_2$ wherein one or both of the C_{1-4} alkyl is optionally substituted with C_{1-6} alkoxy.

3. The compound of claim 1, wherein R^{806} is cyclohexyl substituted by $N(C_{1-4}$ alkyl$)_2$.

4. The compound of claim 1, wherein R^{806} is  .

5. The compound of any of claims 1-4, wherein R^{801} is phenyl or 5- or 6-membered heteroaryl substituted with O-C_{1-6} alkyl-R_x.

6. The compound of claim 1, wherein the compound is of Formula IVa or IVb:



(IVa)

or



(IVb),

wherein Z' is CH or N, and R^{807} is C_{2-3} alkyl-R_x.

7. The compound of claim 6, wherein R^{807} is $-CH_2CH_2OH$, $-CH_2CH_2OCH_3$, or $-CH_2CH_2OCH_2CH_2OCH_3$.

8. The compound of any of claims 1-7, wherein R^{802} is methyl or isopropyl and R^{803} is methyl or methoxyl.

9. The compound of any of claims 1-8, wherein R^{804} is methyl.

10. A compound of Formula I:



(I)

or a pharmaceutically acceptable salt thereof; wherein

R^{701} is H, F, OR^{707}, NHR^{707}, $-(C\equiv C)-(CH_2)_{n7}-R^{708}$, phenyl, 5- or 6-membered heteroaryl, C_{3-8} cycloalkyl, or 4-7 membered heterocycloalkyl containing 1-3 heteroatoms, wherein the phenyl, 5- or 6-membered heteroaryl, C_{3-8} cycloalkyl or 4-7 membered heterocycloalkyl each independently is optionally substituted with one or more groups selected from halo, C_{1-3} alkyl, OH, $O-C_{1-6}$ alkyl, $NH-C_{1-6}$ alkyl, and, C_{1-3} alkyl substituted with C_{3-8} cycloalkyl or 4-7 membered heterocycloalkyl containing 1-3 heteroatoms, wherein each of the $O-C_{1-6}$ alkyl and $NH-C_{1-6}$ alkyl is optionally substituted with hydroxyl, $O-C_{1-3}$ alkyl or $NH-C_{1-3}$ alkyl, each of the $O-C_{1-3}$ alkyl and $NH-C_{1-3}$ alkyl being optionally further substituted with $O-C_{1-3}$ alkyl or $NH-C_{1-3}$ alkyl;

each of R^{702} and R^{703}, independently is H, halo, C_{1-4} alkyl, C_{1-6} alkoxyl or C_6-C_{10} aryloxy, each optionally substituted with one or more halo;

each of R^{704} and R^{705}, independently is C_{1-4} alkyl;

R^{706} is cyclohexyl substituted by $N(C_{1-4}$ alkyl$)_2$ wherein one or both of the C_{1-4} alkyl is substituted with C_{1-6} alkoxy; or R^{706} is tetrahydropyranyl;

R^{707} is C_{1-4} alkyl optionally substituted with one or more groups selected from hydroxyl, C_{1-4} alkoxy, amino, mono- or di-C_{1-4} alkylamino, C_{3-8} cycloalkyl, and 4-7 membered heterocycloalkyl containing 1-3 heteroatoms, wherein the C_{3-8} cycloalkyl or 4-7 membered heterocycloalkyl each independently is further optionally substituted with C_{1-3} alkyl;

R^{708} is C_{1-4} alkyl optionally substituted with one or more groups selected from OH, halo, and C_{1-4} alkoxy, 4-7 membered heterocycloalkyl containing 1-3 heteroatoms, or $O-C_{1-6}$ alkyl, wherein the 4-7 membered heterocycloalkyl can be optionally further substituted with OH or C_{1-6} alkyl; and

n_7 is 0, 1 or 2, provided that the compound is not  or  .

11. The compound of claim 10, wherein R^{706} is cyclohexyl substituted by $N(C_{1-4}$ alkyl$)_2$ wherein one of the C_{1-4} alkyl is unsubstituted and the other is substituted with methoxy.

12. The compound of claim 10, wherein R^{706} is  .

13. The compound of claim 10, wherein the compound is of Formula II:



(II).

14. The compound of any of claims 10-13, wherein R^{702} is methyl or isopropyl and R^{703} is methyl or methoxyl.

15. The compound of any of claims 10-14, wherein R^{704} is methyl.

16. The compound of any of claims 10-15, wherein R^{701} is OR^{707} and R^{707} is C_{1-3} alkyl optionally substituted with OCH_3 or morpholine.

17. The compound of any of claims 10-15, wherein R^{701} is H or F.

18. The compound of any of claims 10-15, wherein R^{701} is tetrahydropyranyl, phenyl, pyridyl, pyrimidyl, pyrazinyl, imidazolyl, or pyrazolyl, each of which is optionally substituted with methyl, methoxy, ethyl substituted with morpholine, or $-OCH_2CH_2OCH_3$.

19. The compound of any of claims 10-18, wherein R^{708} is morpholine, piperidine, piperazine, pyrrolidine, diazepane, or azetidine, each of which is optionally substituted with OH or C_{1-6} alkyl.

20. The compound of any of claims 10-18, wherein R^{708} is morpholine

21. The compound of any of claims 10-18, wherein R^{708} is piperazine substituted with C_{1-6} alkyl.

22. The compound of any of claims 10-18, wherein R^{708} is methyl, t-butyl or $C(CH_3)_2OH$.

23. A compound of Formula VI:



(VI)

or a pharmaceutically acceptable salt thereof;

wherein

n_5 is 0, 1, or 2;

R^{501} is C(H) or N;

R^{502}, R^{503}, R^{504} and R^{505} are, independently for each occurrence, C_{1-4} alkyl;

R^{506} is cyclohexyl substituted by $N(C_{1-4}$ alkyl$)_2$ or piperidine substituted by 1, 2, or 3 C_{1-4} alkyl groups;

when R^{501} is C(H), R^{507} is morpholine; piperidine; diazepane; pyrrolidine; azetidine; O-C_{1-6} alkyl; or O-heterocycle, wherein the heterocycle is a 4-7 membered heterocycle containing an oxygen or nitrogen, or both, and wherein the nitrogen can optionally be substituted with C_{1-3} alkyl; wherein the piperidine, diazepane, pyrrolidine or azetidine groups can be optionally further substituted with OH, C_{1-6} alkyl, or O-C_{1-3} alkyl;

or when R^{501} is C(H), R^{507} can be piperazine optionally further substituted with C_{1-6} alkyl, provided that R^{506} is piperidine substituted by 1, 2, or 3 C_{1-4} alkyl groups;

when R^{501} is N, R^{507} is morpholine; piperidine; piperazine; diazepane; pyrrolidine; azetidine; O-C_{1-6} alkyl; or O-heterocycle, wherein the heterocycle is a 4-7 membered heterocycle containing an oxygen or nitrogen, or both, and wherein the nitrogen can optionally be substituted with C_{1-3} alkyl; wherein the piperidine, piperazine, diazepane, pyrrolidine or azetidine groups can be optionally further substituted with OH, C_{1-6} alkyl, or O-C_{1-3} alkyl.

24. The compound of claim 23, wherein R^{501} is C(H), and R^{507} is piperidine; diazepane; pyrrolidine; azetidine; O-C_{1-6} alkyl; or O-heterocycle, wherein the heterocycle is a 4-7 membered heterocycle containing an oxygen or nitrogen, or both, and wherein the nitrogen can optionally be substituted with C_{1-3} alkyl; wherein the piperidine, diazepane, pyrrolidine or azetidine groups can be optionally further substituted with OH, C_{1-6} alkyl, or O-C_{1-3} alkyl.

25. The compound of claim 23, wherein R^{501} is C(H) and R^{507} is piperidine, diazepane, pyrrolidine, azetidine or O-C_{1-6} alkyl, wherein the piperidine, diazepane, pyrrolidine or azetidine groups can be optionally further substituted with OH or C_{1-6} alkyl.

26. The compound of claim 23, wherein R^{501} is C(H), R^{507} is piperazine optionally further substituted with C_{1-6} alkyl, and R^{506} is piperidine substituted by 1, 2, or 3 C_{1-4} alkyl groups.

27. The compound of claim 23, wherein R^{501} is N, and R^{507} is morpholine, piperidine, piperazine, diazepane, pyrrolidine, azetidine or O-C_{1-6} alkyl, wherein the piperidine, piperazine, diazepane, pyrrolidine or azetidine groups can be optionally further substituted with OH or C_{1-6} alkyl.

28. The compound of claim 23, wherein R^{502} is methyl or isopropyl, and R^{503} is methyl.

29 The compound of any of claims 23-28, wherein R^{504} is methyl.

30. The compound of any of claims 23-29, wherein R^{505} is ethyl.

31. The compound of any of claims 23-30, wherein R^{506} is



or



32. The compound of any of claims 23-30, wherein R^{506} is



33. The compound of any of claims 23-32, wherein when R^{501} is C(H), R^{507} is piperidine or diazepane, which are substituted with OH or C_{1-6} alkyl, or when R^{501} is N, R^{507} is piperidine, piperazine, or diazepane, which are optionally further substituted with OH or C_{1-6} alkyl.

34. The compound of any of claims 23-33, wherein when R^{501} is C(H), R^{507} is piperidine substituted with C_{1-6} alkyl, or when R^{501} is N, R^{507} is piperidine substituted with OH or piperazine substituted with C_{1-6} alkyl.

35. The compound of any of the claims 23-34, wherein when R^{501} is N, R^{507} is unsubstituted piperazine.

36. The compound of claims 23-35, wherein n_5 is 0 or 1.

37. The compound of claim 23, wherein when R^{501} is C(H) or N, R^{507} is O-C_{1-6} alkyl or O-heterocycle, and n_5 is 1.

38. The compound of claim 23, wherein when R^{501} is C(H), R^{507} is unsubstituted piperazine and R^{506} is piperidine substituted by 1, 2, or 3 C_{1-4} alkyl groups.

39. A compound of Formula VII:



(VII)

or a pharmaceutically acceptable salt thereof;

wherein

n_6 is 1 or 2;

R^{602}, R^{603}, R^{604} and R^{605} are, independently for each occurrence, C_{1-4} alkyl;

R^{606} is cyclohexyl substituted by $N(C_{1-4}$ alkyl$)_2$ or piperidine substituted by 1, 2, or 3 C_{1-4} alkyl groups; and

R^{607} is morpholine, piperidine, piperazine, pyrrolidine, diazepane, azetidine or O-C_{1-6} alkyl, wherein the piperidine, diazepane or azetidine groups can be optionally further substituted with OH or C_{1-6} alkyl.

40. The compound of claim 39, wherein R^{602} is methyl or isopropyl and R^{603} is methyl.

41. The compound of claim 39 or 40, wherein R^{604} is methyl and R^{605} is ethyl.

42. The compound of any of claims 39-41, wherein R^{606} is



or



43. The compound of any of claims 39-42, wherein R^{606} is



44. The compound of any of claims 39-43, wherein R^{607} is piperidine or diazepane, each of which is substituted with OH or C_{1-6} alkyl.

45. The compound of any of claims 39-43, wherein R^{607} is piperidine substituted with OH.

46. The compound of any of claims 39-45, wherein n_6 is 2.

47. A compound selected from those in Tables 1A and 1B, and pharmaceutically acceptable salts thereof.

48. A pharmaceutical composition comprising a compound of any of claims 1-47 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

49. Use of a compound of any of claims 1-47 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament in the treatment of an EZH2-medicated disorder.

50. The use of claim 49, wherein the EZH2-mediated disorder is cancer.

51. The use of claim 50, wherein the cancer is lymphoma, leukemia or melanoma.

52. The use of claim 50, wherein the cancer is diffuse large B-cell lymphoma (DLBCL), non-Hodgkin's lymphoma (NHL), follicular lymphoma, chronic myelogenous leukemia (CML), acute myeloid leukemia, acute lymphocytic leukemia, mixed lineage leukemia, or myelodysplastic syndromes (MDS).

53. The use of claim 50, wherein the cancer is malignant rhabdoid tumor or INI1-defecient tumor.

54. A compound of any of claims 1-47 for use in a method of treating an EZH2-mediated disorder.

55. A pharmaceutical composition for treating an EZH2-mediated disorder comprising a compound of any of claims 1-47 as a main ingredient.

What is claimed is:

1. A compound of Formula III:



(III)

or a pharmaceutically acceptable salt thereof; wherein

R^{801} is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, 4-7 membered heterocycloalkyl containing 1-3 heteroatoms, phenyl or 5- or 6-membered heteroaryl, each of which is substituted with O-C_{1-6} alkyl-R_x or NH-C_{1-6} alkyl-R_x, wherein R_x is hydroxyl, O-C_{1-3} alkyl or NH-C_{1-3} alkyl, and R_x is optionally further substituted with O-C_{1-3} alkyl or NH-C_{1-3} alkyl except when R_x is hydroxyl; and R^{801} is optionally further substituted;

each of R^{802} and R^{803}, independently is H, halo, C_{1-4} alkyl, C_{1-6} alkoxyl or C_6-C_{10} aryloxy, each optionally substituted with one or more halo;

each of R^{804} and R^{805}, independently is C_{1-4} alkyl; and

R^{806} is  , provided that the compound is not  .

2. The compound of claim 1, wherein R^{801} is phenyl or 5- or 6-membered heteroaryl substituted with O-C_{1-6} alkyl-R_x.

3. The compound of claim 1, wherein the compound is of Formula IVa or IVb:



(IVa) or



(IVb),

wherein Z' is CH or N, and R^{807} is C_{2-3} alkyl-R_x.

4. The compound of claim 3, wherein R^{807} is $-CH_2CH_2OH$, $-CH_2CH_2OCH_3$, or $-CH_2CH_2OCH_2CH_2OCH_3$.

5. The compound of any of claims 1-4, wherein R^{802} is methyl or isopropyl and R^{803} is methyl or methoxyl.

6. The compound of any of claims 1-5, wherein R^{804} is methyl.

7. A compound of Formula I:



(I)

or a pharmaceutically acceptable salt thereof; wherein

R^{701} is H, F, OR^{707}, NHR^{707}, $-(C\equiv C)-(CH_2)_{n7}-R^{708}$, phenyl, 5- or 6-membered heteroaryl, C_{3-8} cycloalkyl, or 4-7 membered heterocycloalkyl containing 1-3 heteroatoms, wherein the phenyl, 5- or 6-membered heteroaryl, C_{3-8} cycloalkyl or 4-7 membered heterocycloalkyl each independently is optionally substituted with one or more groups selected from halo, C_{1-3} alkyl, OH, O-C_{1-6} alkyl, NH-

C_{1-6} alkyl, and, C_{1-3} alkyl substituted with C_{3-8} cycloalkyl or 4-7 membered heterocycloalkyl containing 1-3 heteroatoms, wherein each of the O-C_{1-6} alkyl and NH-C_{1-6} alkyl is optionally substituted with hydroxyl, O-C_{1-3} alkyl or NH-C_{1-3} alkyl, each of the O-C_{1-3} alkyl and NH-C_{1-3} alkyl being optionally further substituted with O-C_{1-3} alkyl or NH-C_{1-3} alkyl;

each of R^{702} and R^{703}, independently is H, halo, C_{1-4} alkyl, C_{1-6} alkoxyl or C_6-C_{10} aryloxy, each optionally substituted with one or more halo;

each of R^{704} and R^{705}, independently is C_{1-4} alkyl;

R^{706} is cyclohexyl substituted by N(C_{1-4} alkyl)$_2$, wherein one of the C_{1-4} alkyl is unsubstituted and the other is substituted with methoxy;

R^{707} is C_{1-4} alkyl optionally substituted with one or more groups selected from hydroxyl, C_{1-4} alkoxy, amino, mono- or di-C_{1-4} alkylamino, C_{3-8} cycloalkyl, and 4-7 membered heterocycloalkyl containing 1-3 heteroatoms, wherein the C_{3-8} cycloalkyl or 4-7 membered heterocycloalkyl each independently is further optionally substituted with C_{1-3} alkyl;

R^{708} is C_{1-4} alkyl optionally substituted with one or more groups selected from OH, halo, and C_{1-4} alkoxy, 4-7 membered heterocycloalkyl containing 1-3 heteroatoms, or O-C_{1-6} alkyl, wherein the 4-7 membered heterocycloalkyl can be optionally further substituted with OH or C_{1-6} alkyl; and

n_7 is 0, 1 or 2, provided that the compound is not  or  .

8. The compound of claim 7, wherein R^{706} is 

.

9. The compound of claim 7, wherein the compound is of Formula II:



(II).

10. The compound of any of claims 7-9, wherein R^{702} is methyl or isopropyl and R^{703} is methyl or methoxyl.

11. The compound of any of claims 7-10, wherein R^{704} is methyl.

12. The compound of any of claims 7-11, wherein R^{701} is OR^{707} and R^{707} is C_{1-3} alkyl optionally substituted with OCH_3 or morpholine.

13. The compound of any of claims 7-11, wherein R^{701} is H or F.

14. The compound of any of claims 7-11, wherein R^{701} is tetrahydropyranyl, phenyl, pyridyl, pyrimidyl, pyrazinyl, imidazolyl, or pyrazolyl, each of which is optionally substituted with methyl, methoxy, ethyl substituted with morpholine, or $-OCH_2CH_2OCH_3$.

15. The compound of any of claims 7-14, wherein R^{708} is morpholine, piperidine, piperazine, pyrrolidine, diazepane, or azetidine, each of which is optionally substituted with OH or C_{1-6} alkyl.

16. The compound of any of claims 7-14, wherein R^{708} is morpholine

17. The compound of any of claims 7-14, wherein R^{708} is piperazine substituted with C_{1-6} alkyl.

18. The compound of any of claims 7-14, wherein R^{708} is methyl, t-butyl or $C(CH_3)_2OH$.

19. A compound of Formula VI:



(VI)

or a pharmaceutically acceptable salt thereof;

wherein

n_5 is 0, 1, or 2;

R^{501} is C(H) or N;

R^{502}, R^{503}, R^{504} and R^{505} are, independently for each occurrence, C_{1-4} alkyl;

R^{506} is cyclohexyl substituted by $N(C_{1-4}$ alkyl$)_2$ or piperidine substituted by 1, 2, or 3 C_{1-4} alkyl groups;

when R^{501} is C(H), R^{507} is morpholine; piperidine; diazepane; pyrrolidine; azetidine; O-C_{1-6} alkyl; or O-heterocycle, wherein the heterocycle is a 4-7 membered heterocycle containing an oxygen or nitrogen, or both, and wherein the nitrogen can optionally be substituted with C_{1-3} alkyl; wherein the piperidine, diazepane, pyrrolidine or azetidine groups can be optionally further substituted with OH, C_{1-6} alkyl, or O-C_{1-3} alkyl;

or when R^{501} is C(H), R^{507} can be piperazine optionally further substituted with C_{1-6} alkyl, provided that R^{506} is piperidine substituted by 1, 2, or 3 C_{1-4} alkyl groups;

when R^{501} is N, R^{507} is morpholine; piperidine; piperazine; diazepane; pyrrolidine; azetidine; O-C_{1-6} alkyl; or O-heterocycle, wherein the heterocycle is a 4-7 membered heterocycle containing an oxygen or nitrogen, or both, and wherein the nitrogen can optionally be substituted with C_{1-3} alkyl; wherein the piperidine, piperazine, diazepane, pyrrolidine or azetidine groups can be optionally further substituted with OH, C_{1-6} alkyl, or O-C_{1-3} alkyl.

20. The compound of claim 19, wherein R^{501} is C(H), and R^{507} is piperidine; diazepane; pyrrolidine; azetidine; O-C_{1-6} alkyl; or O-heterocycle, wherein the heterocycle is a 4-7 membered heterocycle containing an oxygen or nitrogen, or both, and wherein the nitrogen can optionally be substituted with C_{1-3} alkyl; wherein the piperidine, diazepane, pyrrolidine or azetidine groups can be optionally further substituted with OH, C_{1-6} alkyl, or O-C_{1-3} alkyl.

21. The compound of claim 19, wherein R^{501} is C(H) and R^{507} is piperidine, diazepane, pyrrolidine, azetidine or O-C_{1-6} alkyl, wherein the piperidine, diazepane, pyrrolidine or azetidine groups can be optionally further substituted with OH or C_{1-6} alkyl.

22. The compound of claim 19, wherein R^{501} is C(H), R^{507} is piperazine optionally further substituted with C_{1-6} alkyl, and R^{506} is piperidine substituted by 1, 2, or 3 C_{1-4} alkyl groups.

23. The compound of claim 19, wherein R^{501} is N, and R^{507} is morpholine, piperidine, piperazine, diazepane, pyrrolidine, azetidine or O-C_{1-6} alkyl, wherein the piperidine, piperazine, diazepane, pyrrolidine or azetidine groups can be optionally further substituted with OH or C_{1-6} alkyl.

24. The compound of claim 19, wherein R^{502} is methyl or isopropyl, and R^{503} is methyl.

25 The compound of any of claims 19-24, wherein R^{504} is methyl.

26. The compound of any of claims 19-25, wherein R^{505} is ethyl.

27. The compound of any of claims 1-26, wherein R^{506} is



or



.

28. The compound of any of claims 19-27, wherein R^{506} is



.

29. The compound of any of claims 19-28, wherein when R^{501} is C(H), R^{507} is piperidine or diazepane, which are substituted with OH or C_{1-6} alkyl, or when R^{501} is N, R^{507} is piperidine, piperazine, or diazepane, which are optionally further substituted with OH or C_{1-6} alkyl.

30. The compound of any of claims 19-29, wherein when R^{501} is C(H), R^{507} is piperidine substituted with C_{1-6} alkyl, or when R^{501} is N, R^{507} is piperidine substituted with OH or piperazine substituted with C_{1-6} alkyl.

31. The compound of any of the claims 19-30, wherein when R^{501} is N, R^{507} is unsubstituted piperazine.

32. The compound of claims 19-31, wherein n_5 is 0 or 1.

33. The compound of claim 19, wherein when R^{501} is C(H) or N, R^{507} is O-C_{1-6} alkyl or O-heterocycle, and n_5 is 1.

34. The compound of claim 19, wherein when R^{501} is C(H), R^{507} is unsubstituted piperazine and R^{506} is piperidine substituted by 1, 2, or 3 C_{1-4} alkyl groups.

35. A compound of Formula VII:



(VII)

or a pharmaceutically acceptable salt thereof;

wherein

n_6 is 1 or 2;

R^{602}, R^{603}, R^{604} and R^{605} are, independently for each occurrence, C_{1-4} alkyl;

R^{606} is cyclohexyl substituted by $N(C_{1-4}$ alkyl$)_2$ or piperidine substituted by 1, 2, or 3 C_{1-4} alkyl groups; and

R^{607} is morpholine, piperidine, piperazine, pyrrolidine, diazepane, azetidine or O-C_{1-6} alkyl, wherein the piperidine, diazepane or azetidine groups can be optionally further substituted with OH or C_{1-6} alkyl.

36. The compound of claim 35, wherein R^{602} is methyl or isopropyl and R^{603} is methyl.

37. The compound of claim 35 or 36, wherein R^{604} is methyl and R^{605} is ethyl.

38. The compound of any of claims 35-37, wherein R^{606} is



or



.

39. The compound of any of claims 35-38, wherein R^{606} is



.

40. The compound of any of claims 35-39, wherein R^{607} is piperidine or diazepane, each of which is substituted with OH or C_{1-6} alkyl.

41. The compound of any of claims 35-39, wherein R^{607} is piperidine substituted with OH.

42. The compound of any of claims 35-40, wherein n_6 is 2.

43. A compound selected from those in Tables 1A and 1B, and pharmaceutically acceptable salts thereof.

44. A pharmaceutical composition comprising a compound of any of claims 1-43 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

45. Use of a compound of any of claims 1-43 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament in the treatment of an EZH2-medicated disorder.

46. The use of claim 42, wherein the EZH2-mediated disorder is cancer.

47. The use of claim 46, wherein the cancer is lymphoma, leukemia or melanoma.

48. The use of claim 46, wherein the cancer is diffuse large B-cell lymphoma (DLBCL), non-Hodgkin's lymphoma (NHL), follicular lymphoma, chronic myelogenous leukemia (CML), acute myeloid leukemia, acute lymphocytic leukemia, mixed lineage leukemia, or myelodysplastic syndromes (MDS).

49. The use of claim 46, wherein the cancer is malignant rhabdoid tumor or INI1-defecient tumor.

50. A pharmaceutical composition for treating an EZH2-mediated disorder comprising a compound of any of claims 1-43 as a main ingredient.